Tanabe Pharma

News

LEO Pharma is betting up to $435m on a pill that could give people with an ultra-rare light sensitivity disorder a way to spend more time outdoors.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.